Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The DNA damage response and cancer therapy.

Lord CJ, Ashworth A.

Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760. Review.

PMID:
22258607
2.

Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling.

Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo JA, Davis D, Kirkpatrick DS, Polakis P, Costa M.

PLoS One. 2011;6(7):e22595. doi: 10.1371/journal.pone.0022595. Epub 2011 Jul 25.

3.

Integrated genomic analyses of ovarian carcinoma.

Cancer Genome Atlas Research Network.

Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166. Erratum in: Nature. 2012 Oct 11;490(7419):298.

4.

RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling.

Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, Schirle M, Shi X, Hild M, Bauer A, Myer VE, Finan PM, Porter JA, Huang SM, Cong F.

Nat Cell Biol. 2011 May;13(5):623-9. doi: 10.1038/ncb2222. Epub 2011 Apr 10.

PMID:
21478859
5.

Triple-negative breast cancer.

Foulkes WD, Smith IE, Reis-Filho JS.

N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389. Review.

PMID:
21067385
6.

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ.

Br J Cancer. 2010 Nov 9;103(10):1588-96. doi: 10.1038/sj.bjc.6605946. Epub 2010 Oct 26.

7.

Ex vivo supplementation with nicotinic acid enhances cellular poly(ADP-ribosyl)ation and improves cell viability in human peripheral blood mononuclear cells.

Weidele K, Kunzmann A, Schmitz M, Beneke S, Bürkle A.

Biochem Pharmacol. 2010 Oct 1;80(7):1103-12. doi: 10.1016/j.bcp.2010.06.010. Epub 2010 Jun 25.

PMID:
20599792
8.

Toward a unified nomenclature for mammalian ADP-ribosyltransferases.

Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F.

Trends Biochem Sci. 2010 Apr;35(4):208-19. doi: 10.1016/j.tibs.2009.12.003. Epub 2010 Jan 26. Review.

PMID:
20106667
9.

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F.

Nature. 2009 Oct 1;461(7264):614-20. doi: 10.1038/nature08356. Epub 2009 Sep 16.

PMID:
19759537
10.

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Watson M, Roulston A, Bélec L, Billot X, Marcellus R, Bédard D, Bernier C, Branchaud S, Chan H, Dairi K, Gilbert K, Goulet D, Gratton MO, Isakau H, Jang A, Khadir A, Koch E, Lavoie M, Lawless M, Nguyen M, Paquette D, Turcotte E, Berger A, Mitchell M, Shore GC, Beauparlant P.

Mol Cell Biol. 2009 Nov;29(21):5872-88. doi: 10.1128/MCB.00112-09. Epub 2009 Aug 24.

11.

Nampt: linking NAD biology, metabolism and cancer.

Garten A, Petzold S, Körner A, Imai S, Kiess W.

Trends Endocrinol Metab. 2009 Apr;20(3):130-8. doi: 10.1016/j.tem.2008.10.004. Epub 2008 Dec 26. Review.

12.

GammaH2AX and cancer.

Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y.

Nat Rev Cancer. 2008 Dec;8(12):957-67. doi: 10.1038/nrc2523. Epub 2008 Nov 13. Review.

13.

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.

Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A.

DNA Repair (Amst). 2008 Dec 1;7(12):2010-9. doi: 10.1016/j.dnarep.2008.08.014. Epub 2008 Oct 15.

PMID:
18832051
14.

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A.

EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3.

15.

Resistance to therapy caused by intragenic deletion in BRCA2.

Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A.

Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10.

PMID:
18264088
16.

Minimizing the risk of reporting false positives in large-scale RNAi screens.

Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC, Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey-Prévôt B, Root DE, Sabatini DM, Taipale J, Perrimon N, Bernards R.

Nat Methods. 2006 Oct;3(10):777-9.

PMID:
16990807
17.

Analysis of cell-based RNAi screens.

Boutros M, Brás LP, Huber W.

Genome Biol. 2006;7(7):R66.

18.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A.

Nature. 2005 Apr 14;434(7035):917-21.

19.

Hallmarks of 'BRCAness' in sporadic cancers.

Turner N, Tutt A, Ashworth A.

Nat Rev Cancer. 2004 Oct;4(10):814-9. doi: 10.1038/nrc1457. Review.

PMID:
15510162
20.

Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.

Drevs J, Löser R, Rattel B, Esser N.

Anticancer Res. 2003 Nov-Dec;23(6C):4853-8.

PMID:
14981935

Supplemental Content

Support Center